Business
INVO BIOSCIENCE ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF SHAREHOLDERS
SARASOTA, Fla., Sept. 29, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company") today announced that its special meeting of
About this update from Invo Fertility, Inc.
[{"type":"text","content":"SARASOTA, Fla., Sept. 29, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) (\"INVO\" or the \"Company\") today announced that its special meeting of shareholders on September 29, 2023 (the \"Special Meeting\") was convened and then adjourned, without conducting any business, in order to provide shareholders additional time within which to vote on the proposals as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 1, 2023 (the \"Proxy Statement\").\n\nThe adjourned Special Meeting will reconvene on October 13, 2023 at 12:00 p.m. Eastern Time at www.virtualshareholdermeeting.com/INVO2023SM. The record date of August 21, 2023 for the adjourned Special Meeting remains the same. Shareholders of record may attend the virtual webcast meeting by logging in through the same method.\nDuring this adjournment, the Company will continue to solicit votes from its shareholders in favor of (i) Proposal 1 to approve an increase to the number of authorized shares of common stock of the Company from 6,250,000 shares to 50,000,000 shares, and (ii) Proposal 2 to approve, for the purposes of Nasdaq Marketplace Rule 5635(d), the reduction of the exercise price for the March 2023 private placement warrants from $12.60 per share to $2.85 per share. The Company is required to receive the affirmative vote of the holders of a majority of the outstanding shares for Proposal 1 to pass. At the time of the Special Meeting's adjournment, Proposal 1 had received the affirmative vote of holders of more than 83% of the shares casting votes with approximately 45% of the outstanding shares having cast votes in favor of Proposal 1. The Company is required to receive the affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively (excluding abstentions) at the Special Meeting by the holders entitled to vote thereon for Proposal 2 to pass. At the time of the Special Meeting's adjournment, Proposal 2 had received the affirmative vote of holders of more than 42% of the shares casting votes.\nShareholders who have already voted their shares on the proposals contained in the Proxy Statement do not need to vote again. Proxies previously submitted will be voted at the adjourned Special Meeting, and shareholders who have previously submitted a proxy or ot...